BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Mallinckrodt
UBS
Merck
Medtronic
McKinsey
Moodys
Daiichi Sankyo
Fuji
McKesson

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,144,884

« Back to Dashboard

Which drugs does patent 7,144,884 protect, and when does it expire?

Patent 7,144,884 protects TRINTELLIX and is included in one NDA.

This patent has seventy patent family members in thirty-six countries.
Summary for Patent: 7,144,884
Title:Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder ##STR00001##
Inventor(s): Ruhland; Thomas (Roskilde, DK), Smith; Garrick Paul (Valby, DK), Bang-Andersen; Benny (Copenhagen, DK), Puschl; Ask (Frederiksberg, DK), Moltzen; Ejner Knud (Gentofte, DK), Andersen; Kim (Ridgewood, NJ)
Assignee: H. Lundbeck A/S (Copenhagen-Valby, DK)
Application Number:10/488,280
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,144,884

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-001 Sep 30, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y Y METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION ➤ Subscribe
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-002 Sep 30, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y Y METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION ➤ Subscribe
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-003 Sep 30, 2013 DISCN Yes No ➤ Subscribe ➤ Subscribe Y Y METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION ➤ Subscribe
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,144,884

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2001 01466Oct 04, 2001
PCT Information
PCT FiledOctober 02, 2002PCT Application Number:PCT/DK02/00659
PCT Publication Date:April 10, 2003PCT Publication Number: WO03/029232

Non-Orange Book US Patents Family Members for Patent 7,144,884

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,138,407 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Subscribe
9,708,280 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Subscribe
8,476,279 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Subscribe
9,090,575 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Subscribe
7,148,238 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Subscribe
7,683,053 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Subscribe
8,110,567 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,144,884

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Serbia 20120158 ➤ Subscribe
Serbia 52326 ➤ Subscribe
Serbia 27704 ➤ Subscribe
Portugal 1749818 ➤ Subscribe
Portugal 1436271 ➤ Subscribe
Poland 210551 ➤ Subscribe
Poland 209253 ➤ Subscribe
Poland 368442 ➤ Subscribe
New Zealand 531556 ➤ Subscribe
Norway 2014011 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Novartis
Johnson and Johnson
Accenture
McKesson
Argus Health
QuintilesIMS
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot